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Glucocorticoids (GC) induce cardiometabolic risk while atherosclerosis is a chronic inflammation involving immunity. GC are
immune suppressors, and the adrenocorticotrophic hormone (ACTH) has immune modulator activities. Both may act in
atherothrombotic inflammation involving immune cells (IMNC). Aim. To investigate adhesion and activation surface cell
markers (CDs) of peripheral IMNC in endogenous Cushing syndrome (CS) and the immune modulator role of ACTH. Material
and Methods. 16 ACTH-dependent CS (ACTH-D), 10 ACTH-independent (ACTH-ID) CS, and 16 healthy controls (C) were
included. Leukocytes (Leuc), monocytes (MN), lymphocytes (Lym), and neutrophils (N) were analyzed by flow cytometry
for atherosclerosis previously associated with CDs. Results. Leuc, N, and MN correlated with CS (p < 0 05), WC (p < 0 001),
WHR (p = 0 003), BMI (p < 0 001), and hs-CRP (p < 0 001). CD14++CD16+ (p = 0 047); CD14+CD16++ (p = 0 053) MN; CD15+
(p = 0 027); CD15+CD16+ (p = 0 008) N; and NK-Lym (p = 0 019) were higher in CS. CD14+CD16++ MN were higher in
ACTH-ID (8.9± 3.5%) versus ACTH-D CS (4.2± 1.9%) versus C (4.9± 2.3%). NK-Lym correlated with c-LDL (r= 0.433,
p = 0 039) and CD15+ N with hs-CRP (r= 0.446, p = 0 037). In multivariate analysis, Leuc, N, and MN depended on BMI
(p = 0 021), WC (p = 0 002), and WHR (p = 0 014), while CD15+ and CD15+CD16+ N on hypercortisolism and CS (p = 0 035).
Conclusion. In CS, IMNC present changes in activation and adhesion CDs implicated in atherothrombotic inflammation.
ACTH-IDCS presents a particular IMNC phenotype, possibly due to the absence of the immune modulator effect of ACTH.
1. Introduction
Chronic hypercortisolism, regardless of its exogenous or
endogenous etiology, is marked by an increased cardiometa-
bolic risk pattern consisting of abdominal visceral adiposity,
arterial hypertension, insulin resistance/impaired glucose
tolerance/type 2 diabetes mellitus (T2D), dyslipidemia, and
hypercoagulability, all leading to premature atherosclerosis
and increased cardiovascular mortality [1].
What is more is that glucocorticoids (GC) mediate stress
response and exert potent immune-suppressive and anti-
inflammatory effects. Innate and adaptive immunity response
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induced by acute or chronic,mainly exogenous, hypercortiso-
lism has been investigated in different experimental settings.
Both animal and human studies have shown that various
forms of stress are associated with deregulation of the
immune function [2, 3]. Furthermore, neuropeptidic compo-
nents of the hypothalamic-pituitary-adrenal (HPA) axis such
as adrenocorticotrophic hormone (ACTH) and B-endorphin
possess potent immune-modulatory activities [3, 4].
In Cushing syndrome (CS), the prolonged endogenous
exposure to pathologic GC levels induces alterations of the
white blood cell count and function with granulocytosis,
increased monocytes, and a reduced number of lymphocytes
with a decreased CD4/CD8 T ratio and Natural killer (NK)
cell activity [5].
It is widely recognized that atherosclerosis is a chronic
inflammatory state associated with visceral obesity, T2D,
dyslipidemia, and other risk factors [6]. Both innate and
adaptive immunity are involved in this inflammatory
response [7]; the first steps implicate monocytes while later
steps involve CD4, CD8, and NK T lymphocytes as well as
recently demonstrated neutrophils [7–11].
Hence, research on the innate and adaptive immunity
response both in chronic, mostly exogenous, and in acute
experimental-induced hypercortisolism has been performed
so far. GC and ACTH may act both independently and
together in the atherothrombotic inflammatory pathways.
To date, there have been no reports regarding the adhe-
sion and activation of cell surface markers of peripheral
immune cells involved in chronic endogenous hypercortiso-
lism or on the potential immune modulator role of ACTH
on these markers.
In the present study, we analyze the immune cell pattern
in an endogenous hypercortisolemic state in order to investi-
gate their atherovascular risk phenotype and to evaluate the
immune modulator role of ACTH on this pattern. For this
purpose, peripheral immune cells—monocytes, lymphocytes,
and neutrophils from patients with ACTH-dependent CS
(ACTH-D CS) and ACTH-independent CS (ACTH-ID
CS)—were analyzed by flow cytometry and compared with
those in healthy controls.
2. Material and Methods
2.1. Subjects. A cross-sectional study was performed in
endogenous CS patients referred by diagnosis to the Endocri-
nology and Nutrition Department of the Hospital Clínic of
Barcelona between January 2012 and January 2016. All
included subjects were women of Caucasian origin. The
study was approved by the ethical committee of the Hospital
Clinic of Barcelona, and all participants signed an informed
consent. The diagnosis of endogenous CS was established
according to the guidelines of both the European Society of
Endocrinology (ESE) and the Endocrine Society [12] and
shown by repeated elevated levels of urinary free cortisol, loss
of circadian rhythm (elevated free night salivary cortisol),
and the lack of suppression of cortisol secretion after dexa-
methasone. Localization of the cortisol-secreting tumour
was determined by the ACTH level, cortisol suppression test
with 8mg dexamethasone, imaging tests, and inferior
petrosal sinus sampling (IPSS) when necessary [12]. The sub-
jects included were as follows:
(1) Sixteen patients with pituitary ACTH-dependent CS
with age at diagnosis 44.1± 13.5 years.
(2) Ten patients with ACTH-independent CS with age at
diagnosis 43.8± 9.8 years.
(3) Sixteen healthy subjects (age 43.6± 10.3 years)
recruited among the relatives of the CS patients and
volunteers. None presented signs or symptoms of
hypercortisolism, a history of adrenal incidentaloma,
or severe and/or chronic illness. None was taking
exogenous glucocorticoids or drugs that could inter-
fere with the HPA axis. Controls were matched by
age with CS patients.
2.2. Anthropometric and Clinical Parameters. All subjects
were examined after a 10h overnight fast. Weight, height,
BMI, and waist and hip circumference were measured. Fast-
ing blood samples were taken and either stored at −80°C or
directly processed for immune cell phenotyping.
Body weight was measured in light clothing and without
shoes to the nearest 0.1 kg. Height was measured to the near-
est half centimeter. BMI was calculated as weight in kilo-
grams divided by height in square meters (kg/m2). Waist
circumference (WC) was measured at minimal inspiration
to the nearest 0.1 cm, midway between the last rib and the
iliac crest. Hip circumference was measured at the widest of
the buttocks and then calculated the waist/hip ratio (WHR).
2.3. Laboratory Parameters. Blood samples were collected at
8 a.m., after overnight fasting. Main biochemical parameters
were measured in serum with standard methods in the core
laboratory of our hospital. High-sensitivity C-reactive pro-
tein (hs-CRP) was determined using an immunonephelo-
metric method (Boehring Nephelometer analyzer; Dade
Boehring, Marburg, Germany). Plasma glucose, total and
HDL cholesterol, and triglycerides were measured using
ADVIA 2400 (Siemens Healthcare Diagnostics, Tarrytown,
NY, USA), and HbA1C was measured using high-
performance liquid chromatography (A. Menarini Diagnos-
tics, Firenze, Italy).
Insulin was determined in duplicate by an ELISA kit
(Mercodia AB, Uppsala, Sweden) following the manufacturer
instructions. The intra- and interassay CVs were lower than
4% and the assay sensitivity was 1mU/l. Insulin resistance
was calculated according with the homeostasis model assess-
ment (HOMA-IR): insulin resistance = fasting plasma insulin
(μU/ml)× fasting plasma glucose (mmol/l)/22.5.
The hormonal analysis was performed in the hormonal
laboratory of our centre, applying the standard procedures
as follows: ACTH was measured by IRMA (ACTH-IRMA;
DiaSorin, Saluggia, Italy); salivary cortisol was analyzed with
a specifically validated competitive immunoassay (Salimetrics
LLC, State College, Pennsylvania, USA). Serum cortisol was
measured using a chemiluminometric immunoassay ran on
ADVIA Centaur XP Immunochemistry analyzer (Siemens
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Healthcare Diagnostics, Tarrytown, NY, USA). The concen-
tration of 24 h urine cortisol was analyzed by chemilumines-
cence immunoassay (Liaison; DiaSorin, Saluggia, Italy) and
confirmed by gas chromatography mass spectrometry.
2.4. Immune Cell Phenotyping. Fresh whole blood was
obtained after overnight fasting. White cell subpopulations
were analyzed in a 100μl whole-blood assay following
standard protocols [13, 14]. Fluorochrome-conjugated
monoclonal antibodies to cell surface markers of adhesion
and activity were purchased from BD Bioscience (San Diego,
CA, USA) and used in different combinations in order to
analyze lymphocytes (CD16-PeCy7, CD25-Brilliant Blue
605, CD3-FITC, CD4-PECy5′5, CD19-APC, CD11b-AF700,
and CD8-APCCy7) or monocytes/granulocytes (CD16-
PeCy7, CD14-Pacific Blue, CD11b-AF700, and CD15-PE).
Samples were evaluated as follows by blood flow cytometry
using an LSRFortessa™ SORP with the FACSDiva Software
v6.1.3 (both Becton Dickinson).
Counting beads were employed for absolute number
evaluation. The sizes of specific immune cell subsets were
expressed as a percentage of the total white blood cell count.
Monocytes were first gated based on morphological charac-
teristics using their forward (FSC) and side scatter (SSC)
properties. Next, we identified the three main monocyte sub-
populations in a dot plot of CD14 versus CD16: CD14+
+CD16−, CD14++CD16+, and CD14+CD16++. In each of these
populations, the percentages of CD11b+ cells were calculated.
The percentage of total CD14+ cells and CD14+CD11b+ cells
was determined too (Figure 1).
T lymphocytes were defined as CD3+ cells, and we
distinguished between CD3+CD4+ and CD3+CD8+ cells.
Expression of CD25 was analyzed on CD3+CD4+ T cell
subpopulation taking CD3+CD8+ T cells as negative control
for CD25 expression. Next, we established the CD3−CD19+
(B cells) and CD3−CD19− subpopulations in the invert gate
of CD3+ cells (not CD3+ events). In order to define NK cell
population, we gated CD4−CD8− cells and combined them
with CD3−CD19− cells. Then, we show this population in a
CD19 versus CD14 dot plot and select those events, which
were also CD14. Finally, NK cells were defined as
CD3−CD19−CD14−CD16+ events, where we determined the
percentage of NK CD11b+ cells.
Granulocytes were gated according to their morphologi-
cal characteristics and then analyzed for the expression of
CD15, CD16, and CD11b. We calculated the percentage of
CD15+, CD16+ total granulocytes, the percentage of
CD15+CD11b+, CD16+CD11b+, CD15+CD16+ double posi-
tive cells, and also CD15+CD16+CD11b+ triple positive cells.
2.5. Statistical Analysis. Due to our small sample size and the
abnormal distribution of most of the variables with the
Kolmogorov-Smirnov test, we underwent nonparametric
tests to analyze the sample. Quantitative data are expressed
as mean and SD, and qualitative data are expressed as per-
centages. Comparisons between the CS group and controls
were performed using nonparametric tests and between
ACTH-ID and ACTH-D CS and controls using ANOVA test
followed by Bonferroni analysis when assuming equal vari-
ances or Games-Howell when assuming different variances.
Correlations between anthropometric parameters, laboratory
and hormonal parameters, and phenotyping parameters
(immune cells) across the study population were assessed
using the Pearson method. Multivariate analysis was per-
formed to analyze the immune cell dependence from vari-
ables that show significant association in univariate analyses
(BMI, WHR, WC, hs-CRP, 24-UFC, and ACTH). All analy-
ses were performed using SPSS version 22 (SPSS, Chicago, IL,
USA), and the level of significance was established at the
two-sided 5% level.
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Figure 1: Flow cytometry analysis of activation and adhesion cell marker on monocytes in peripheral blood. Monocytes were gated based on
morphological characteristics using their forward (FSC) and side scatter (SSC) properties. CD14++CD16−, CD14++CD16+, and CD14+CD16++
populations were determined and thereafter the % CD11b in each of these populations as well as % of total CD14+ and CD14+CD11b+.
3International Journal of Endocrinology
3. Results
Clinical characteristics of patients and controls are presented
in Table 1. There were no differences in age and BMI among
patients. Patients with CS presented with typical cardiomet-
abolic comorbidities induced by hypercortisolism like insu-
lin-resistance, T2D, hypertension, and obesity. The entire
CS group presented differences in WC, WHR, total and
LDL-c cholesterol, and hs-CRP in relation with controls.
3.1. Immune Cell Phenotyping. Total leukocytes, neutro-
phils, and monocytes were increased in all patients with
CS, both in the ACTH-dependent and ACTH-independent
forms, while there were no differences in lymphocyte
counts (Table 1).
3.1.1. Monocytes. Controls presented an increased percent-
age of classical CD14++CD16−monocytes (p = 0 082), whereas
CD14++CD16+ intermediate monocytes (p = 0 047) were
higher in the CS group, both in the ACTH-dependent
and ACTH-independent forms, with the highest atypical
CD14+CD16++ monocytes in patients with ACTH-
independent CS (p = 0 019). Activated CD11b+ immune cell
phenotypes were increased in all analyzed immune cell sub-
types in patients with ACTH-independent CS, but without
reaching a statistically significant difference (Tables 2 and 3).
3.1.2. Neutrophils. We observed a higher percentage of
CD15+ (p = 0 027) and CD15+CD16+ (p = 0 008) and ten-
dency in CD15+CD16+11b+ neutrophils in the CS group than
in the control, whereas CD16+11b neutrophils showed no
differences (Tables 2 and 3).
3.1.3. Lymphocytes.We observed no differences in lymphocyte
subtypes, except for the prevalence of NK (p = 0 019) lym-
phocytes that were higher in the CS group (Tables 2 and 3).
3.2. Correlations between Immune Cells and Clinical and
Analytical Parameters. A positive correlation was observed
between leukocytes and waist circumference (p < 0 001),
WHR (p = 0 003), BMI (p < 0 001), and hs-CRP (p < 0 001).
The same correlation was observed for neutrophils and
monocytes. NK-lymphocyte positive correlate with c-LDL
(r=0.433, p = 0 039) and CD15+ neutrophils with hs-CRP
(r=0.446, p = 0 037) (Figure 2). In multivariate analysis, we
observed that leukocyte, neutrophil, and monocyte numbers
depend on BMI [p = 0 021, OR: −1.21 (IC: −3.03 to −0.15)],
WC [p = 0 002, OR: 3.15 (IC: 1.21 to 5.03)], and WHR
[p = 0 014, OR: −1.2 (IC: −2.98 to −0.18)]. When we ana-
lyzed the phenotyped immune cells, we observed that
CD15+ neutrophil and CD15+CD16+ neutrophil depend
on the hypercortisolism present only in CS [p = 0 035,
OR: −1.57 (IC: −5.21 to 1.13)].
Table 1: Characteristics of the study population.
Parameters ACTH-dependent CS (n= 16) ACTH-independent CS (n= 10) Control (n= 16) p value
Age (years) 44.1± 13.5 43.8± 9.8 43.9± 10.3 0.869
Leukocytes (mm3) 9460.0± 2429.2 7508.7± 1329.8 5842.0± 1279.2 <0.001∗∗
Neutrophils (mm3) 6562.5± 2093.7 5062.5± 1329.8 3270.0± 960.4 <0.001∗∗
Lymphocytes (mm3) 2031.2± 710.6 1725.0± 549.6 1870.0± 533.4 0.522
Monocytes (mm3) 562.5± 224.7 425.0± 128.1 330.0± 94.8 0.008∗
T2D (%) 5 (31) 3 (30) 0 (0) 0.341
HTA (%) 8 (50) 5 (50) 0 (0) 0.145
DLP (%) 3 (19) 3(30) 0 (0) 0.271
Obesity (%) 8 (50) 5 (50) 1 (6) 0.215
BMI (kg/m2) 29.4± 5.1 29.2± 13.1 24.2± 4.2 0.339
Waist C (cm) 94.7± 14.1 94.2± 18.3 77.5± 11.7 0.037∗
WHR 0.90± 0.1 0.89± 0.1 0.71± 0.1 0.024∗
TC (mmol/l) 5.6± 0.8 5.5± 0.5 4.5± 0.5 0.020∗
TG (mmol/l) 1.4± 0.6 1.4± 0.5 0.9± 0.6 0.238
LDL-c (mmol/l) 3.4± 0.5 3.4± 0.6 2.5± 0.6 0.016
HDL-c (mmol/l) 1.5± 0.4 1.5± 0.3 1.7± 0.6 0.355
Hs-CRP (mg/dl) 0.36± 0.36 0.30± 0.31 0.02± 0.01 0.038∗
Glucose (mmol/l) 6.5± 2.7 6.1± 0.7 5.2± 0.6 0.268
HOMA-IR 3.80± 2.51 3.69± 2.23 2.89± 2.91 0.482
HbA1c (DCCT) 6.8± 1.9 6.6± 0.5 5.4± 0.2 0.076
UFC-24hs (mcg/24hs) 269.2± 114.8 257.7± 118.1 44.8± 12.6 0.029∗
ACTH (pg/ml) 68.4± 73.5 5.6± 1.4 33.5± 7.3 0.023∗
Data are expressed as mean ± standard deviation. Qualitative variables are expressed as percentages. BMI: body mass index; HOMA-IR: homeostasis model
assessment for insulin resistance; T2D: type 2 diabetes; HbA1c (DCCT): haemoglobin A1c (diabetes control and complication trial units); Hs-CRP: high-
sensitivity C-reactive protein; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol;WHR: waist/hip ratio. ∗p < 0 05. ∗∗p < 0 001.
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4. Discussion
The HPA axis modulates in a circadian fashion the endoge-
nous inflammatory and stress response pathways with gluco-
corticoids as final tissue effectors. Immune cells play an
important role in macrovascular inflammation associated to
systemic atherosclerosis perpetuating the inflammatory cir-
culatory environment and the chronic and acute injury of
the activated endothelium [7–11]. Observational studies
have reported that traditional cardiometabolic risk factors
as insulin-resistant visceral obesity, T2D, and dyslipidemia
associate with changes in the peripheral immune cell
pattern [13–22].
Glucocorticoid excess is marked by an increased cardio-
metabolic risk pattern consisting of visceral adiposity, arterial
hypertension, insulin resistance/impaired glucose tolerance/
T2D, dyslipidemia, and hypercoagulability, leading to
premature atherosclerosis and increased cardiovascular
mortality [1]. Interestingly, overphysiologic chronic levels
of endogenous or exogenous GC induce immune suppres-
sion and increased cardiovascular morbidity and mortality
suggesting a possible dual effect of GC on both metabolic
and immune pathways in the atherosclerotic cascade.
Moreover, the role of the upper HPA axis elements, such as
ACTH as a potential immune modulator in atherosclerotic
inflammation, has not yet been evaluated.
Thus, we analyzed the potential effects of GC and ACTH
on the peripheral atherovascular immune cell surface
markers of patients with endogenous ACTH-dependent
and ACTH-independent CS and of healthy controls. We
studied the cell surface adhesion and activation markers pre-
viously associated with chronic atherosclerosis inflammation
in circulatory monocytes, lymphocytes, and neutrophils. The
present study has its limitations: since endogenous CS is a
rare disease, our study population is small and we have
included only women, which may have diminished the
statistical power of our results.
Evidence of immune cell alterations in endogenous CS,
other than the known increased risk of infections observed
in clinical settings, has been accumulated over several
decades. Meanwhile, major knowledge about GC immune
actions has been proven by various studies of innate and
adaptive immunity response in chronic, mostly exogenous
or acute experimental-induced hypercortisolism.
Elevated white blood cell count and neutrophilia associ-
ated with CS were described early in the 1940s [23]. Accord-
ing to epidemiological and experimental data, leukocytosis is
an independent risk factor and predictor of future cardiovas-
cular events [24]. In the late 1990s, Kronfol et al. reported a
relative decrease in the percentage of CD4+ and a relative
increase in that of CD8+ T cells, together with reduced
CD4/CD8 ratio and NK T cell activity, in patients with CS
as compared to matched controls [3]. Later on, Masera
et al. observed both in vivo and in vitro that the spontaneous
and cortisol-dependent percentage inhibitionNK activity was
different in ACTH-dependent versus ACTH-independent
CS. In pituitary-dependent CS, plasma ACTH correlated
positively with mean levels of spontaneous NK activity
and negatively with cortisol-dependent percentage inhibi-
tion. In adrenal-dependent CS, a negative correlation was
observed between spontaneous NK activity and urinary
free cortisol. These findings, suggested an immune modu-
lator role of pituitary pro-opiomelanocortin-derived pep-
tides, like ACTH, that effectively counterbalance, at least
partially, GC immunosuppression [25].
In our series, the correlation analysis between phenotype
markers and immune cells revealed that the CS patients
presented leukocytosis with neutrophilia and monocytosis
that positively correlated with WC, WHR, BMI, and hs-
CRP, an association that persists except for hs-CRP in
multivariate analysis.
Detailed analysis of our results points out compelling
changes in adhesion and activation markers of vascular
inflammation in circulatory immune cells in CS.
Among lymphocytes, NK lymphocytes were significantly
increased in CS and correlated with LDL-cholesterol; unlike
Kronfold et al., we observed that no difference between
ACTH and ACTH-ID CS NK cells has been shown to
react toward lipid antigens presented by CD1 molecules
on antigen-presenting cells and, once activated, to pro-
duce proinflammatory cytokines and promote atheroscle-
rosis [8, 11, 26].
Interestingly, besides an increase in neutrophil number,
as seen in experimental data from hypercortisolemic condi-
tions [27, 28], the neutrophils of all CS patients showed a
Table 2: Cell surface marker phenotyping of immune cells between
CS and controls.
Parameters
Controls
(n= 16)
Cushing
syndrome
(n= 26)
p value
Monocytes
CD14++CD16−
classical (MN)
42.2± 32.5 34.2± 30.1 0.082
CD14++CD16−11b+ (%) 80.8± 19.6 72.4± 32.4 0.227
CD14++CD16+
intermediate (MN)
28.7± 26.1 36.3± 25.1 0.047∗
CD14++CD16+11b+ (%) 48.1± 48.7 52.4± 44.8 0.432
CD14+CD16++
nonclassical (MN)
5.8± 3.8 7.1± 2.3 0.053∗
CD14+CD16++11b+ (%) 35.4± 41.1 38.4± 42.8 0.864
Neutrophils
CD15+ (% N) 47.1± 13.9 65.8± 24.6 0.027∗
CD15+CD16+ (%) 44.3± 12.7 66.6± 25.2 0.008∗
CD15+CD16+11b (%) 69.2± 29.1 80.6± 26.6 0.098
CD16+11b (% N) 94.2± 4.2 90.0± 22.7 0.460
Lymphocytes
CD3+CD8+ (% L) 26.8± 8.0 30.1± 11.9 0.435
CD3+CD4+ (% L) 54.2± 6.6 47.6± 18.6 0.207
CD3+CD4+CD25+ (%) 22.7± 11.1 20.7± 18.8 0.746
NK (% L) 18.4± 18.5 34.7± 32.2 0.019∗
NKCD11b+ (%) 37.5± 44.4 35.1± 36.0 0.889
Data are expressed as %± standard deviation. MN: monocytes; N: neutrophils;
L: lymphocytes. ∗p < 0 05.
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tendency to express activation markers like FC receptor
CD16 and tetrasaccharide adhesion marker CD15, an associ-
ation that persists in multiregression analysis. CD15+ neutro-
phils associated with the higher systemic inflammation
observed in the CS patients. Just a slight tendency for an
increased expression of integrin adhesion molecule CD11b
was observed in ACTH-independent CS.
Sustained clinical evidence supports the association of neu-
trophilia with morbid obesity and metabolic syndrome, as well
as an increased morning cortisol in obese subjects [29, 30].
Table 3: Cell surface marker phenotyping of immune cells.
Parameters ACTH-dependent CS (n= 16) ACTH-independent CS (n= 10) Controls (n= 16) p value
Monocytes
CD14++CD16− classical (% MN) 32.7± 29.2 36.4± 33.8 42.2± 32.5 0.805
CD14++CD16−11b+ (%) 63.4± 37.5 86.6± 15.5 80.8± 19.6 0.195
CD14++CD16+ intermediate (% MN) 37.6± 25.1 34.2± 27.0 28.7± 26.2 0.748
CD14++CD16+11b+ (%) 47.7± 43.7 59.8± 49.1 48.1± 48.7 0.845
CD14+CD16++
Nonclassical (% MN)
4.9± 1.9 8.9± 3.5 5.8± 3.8 0.019∗
CD14+CD16++11b+ (%) 29.1± 38.7 52.9± 48.0 35.4± 41.1 0.608
Neutrophils
CD15+ (% N) 65.5± 27.5 66.3± 21.2 47.1± 13.9 0.205
CD15+CD16+ (%) 64.4± 28.0 70.2± 21.6 44.3± 12.7 0.103
CD15+CD16+ 11b (%) 74.2± 30.7 90.5± 15.3 69.2± 29.1 0.313
CD16+11b (% N) 85.9± 28.8 96.4± 1.5 94.2± 4.2 0.495
Lymphocytes
CD3+CD8+ (% L) 27.9± 14.1 33.2± 8.0 26.8± 8.1 0.496
CD3+CD4+ (%L) 43.6± 21.6 53.4± 12.6 54.2± 6.6 0.300
CD3+CD4+CD25+ (%) 18.7± 16.7 23.7± 22.7 22.7± 11.1 0.813
NK (% L) 30.8± 31.8 40.3± 34.4 18.4± 18.5 0.359
NK CD11b+ (%) 26.4± 31.2 47.6± 40.9 37.5± 44.4 0.541
Data are expressed as % ± standard deviation. MN: monocytes; N: neutrophils; L: lymphocytes. ∗p < 0 05.
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Figure 2: Correlations between leukocytes and clinical and analytical parameters. BMI: body mass index; hs-CRP: high-sensitivity C-reactive
protein; WC: waist circumference; WHR: waist/hip ratio. Total leukocyte, monocyte, and neutrophil number correlates with waist
circumference (p < 0 001), waist/hip ratio (p = 0 003), BMI (p < 0 001), and hs-CRP (p < 0 001).
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The importance of neutrophils in the onset and progres-
sion of atherosclerosis has been recently reported, probably
due to their rapid turnover in atherosclerotic plaque and also
the lack of adequate detection methods. Neutrophils have
been reported as associated with acute coronary events and
as independent predictors of multiple stenosis in chronic
stable angina. In patients with coronary artery disease
undergoing stent implantation, ACTH and cortisol patterns
modulate neutrophil activation. Neutrophils adhere to the
plated-activated endothelium and trigger recruitment of
inflammatory monocytes and T lymphocytes. Thereafter,
they activate proinflammatory cytokine secretion by macro-
phages and interact with T cell subsets. Moreover, in
advanced atherosclerotic lesions, they favor plaque rupture
by secretion of matrix degradation factors [9, 10, 31, 32].
Strikingly, in our series, the analysis of the circulating
monocyte patterns revealed the presence of higher levels of
intermediate CD14++CD16+ and nonclassical CD14+CD16++
cardiovascular risk monocyte phenotypes in CS patients;
among them, the highest levels of atypical monocytes were
observed in ACTH-independent CS patients.
Monocytes have been divided into 3 major subsets
according to the expression intensity of lipopolysaccharide
(LPS) receptor CD14 and FC receptor CD16 [33]. Classical
CD14++CD16− monocytes are professional phagocytes that
ingest native low-density lipoprotein, (LDL), generate reac-
tive oxygen species (ROS) that secrete cytokines in response
to LPS [15], and activate CD4T cells. In contrast, intermediate
CD14++CD16+ and nonclassical or atypical CD14+CD16++
monocytes do not generate ROS and are weak phagocytes tak-
ing up preferentially oxidized LDL, but they are able to control
the endothelium through their capability to crawl on the
endothelium-blood interface. Intermediate CD14++CD16+
monocytes increase in inflammatory and autoimmune condi-
tions and seem to inhibit CD4+ T cell proliferation induced by
othermonocyte subsets and enhanceCD4+T regulatory IL-10
expression. Nonclassical CD 14+CD16++ monocytes are
potent proinflammatory cells related to cardiovascular disease
and substantially secrete inflammatory cytokines, like tumour
necrosis factor-α, interleukin-1β, and CCL3 [15–18]. CD16+
monocytes have been generally associated with traditional
cardiovascular risk factors like insulin-resistant obesity,
systemic low-grade inflammation diabetes, and dyslipidemia
and also with atherosclerosis and acute coronary events.
CD16+ monocytes also actively contribute to infarct healing,
remodeling, and angiogenesis. Nevertheless, the specific role
of monocyte subsets is still at debate [14, 19–22]. Moreover,
no evidence is available on monocyte CD14CD16 profiles in
relation to the HPA axis.
Our results, the first focused on endogenous exposure to
GC, were similar to those of Liu et al., who showed increased
intermediate CD14+CD16+ monocytes after treatment in
patients with autoimmune disease [18]; moreover, GC treat-
ment directly affected CD16 expression. Nevertheless, our
data in CS patients, an endogenous chronic state of hypercor-
tisolism, differ from other previous findings after GC admin-
istration, either acute or subacute, in controls [34] and
patients with inflammatory disorders [35–37] or chronic low
doses in patients with chronic inflammatory diseases [38].
5. Conclusion
We have analyzed for the first time adhesion and activation
of cell surface markers of peripheral immune cells in a
chronic pathologic endogenous hypercortisolemic state.
Here, we report that chronic exposure to high, pathological
levels of GC reaching an overt CS state independently associ-
ates with increased levels of CD15+CD16+ and CD15+ neu-
trophils and correlates with intermediate CD14++CD16+
and nonclassical CD14+CD16++ monocyte induction, due
to the overall effect of GC-induced metabolic features. Possi-
ble exceptions may be the activation of neutrophils which
may have a dual dependency from both metabolic changes
and hypercortisolism pathways per se and also the unique
pattern that characterizes monocyte subset distribution in
ACTH-independent CS. Stronger monocyte changes in
ACTH-independent hypercortisolism may be due to the
absence of the immune-modulatory effect of ACTH. This
study opens new research standpoints concerning the
crosstalk between adrenal axis and leucocyte subsets in
insulin-resistant obesity and their role in metabolic-driven
atherovascular disease.
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